Henrik Jørn Ditzel

43PUBLICATIONS
87CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biologyPredictive and prognostic markersInformation systems development methodologies and practice
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Dec 17, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.

Carla L Alves, Leena Karimi, Mikkel G Terp

|Dec 04, 2025
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial.

Odd Lilleng Gammelgaard, Sidse Ehmsen, Anne Marie Bak Jylling

|Sep 10, 2025
SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast Cancer.

Rikkemaja Isahbell J Møldrup, Mikkel G Terp, Simon T Jakobsen

|Oct 26, 2024
Correction: Mansoori et al. HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer. Cancers 2021, 13, 5197.

Behzad Mansoori, Mikkel Green Terp, Ali Mohammadi

|Aug 11, 2024
Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.

Charlotte K Kindt, Carla L Alves, Sidse Ehmsen

|Jun 17, 2024
Single-cell sequencing unveils extensive intratumoral heterogeneity of cancer/testis antigen expression in melanoma and lung cancer.

Sofie Traynor, Mie K Jakobsen, Tina M Green

Pageof 8

Frequent Collaborators

10 joint publications

Morten Frier Gjerstorff

7 joint publications

Sidse Ehmsen

6 joint publications

Carla L Alves

5 joint publications

Odd Lilleng Gammelgaard